Expand ELTX Menu
ELTX MENU

ELTX Latest Press Releases

-- September 24, 2026 --

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026 Globe Newswire 8:00 AM

-- August 31, 2026 --

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 8:00 AM

-- August 24, 2026 --

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference Globe Newswire 8:00 AM

-- August 13, 2026 --

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 4:01 PM

-- August 10, 2026 --

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma Globe Newswire 8:00 AM

-- July 9, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX PRNewswire 5:20 PM

-- July 7, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX Globe Newswire 5:28 PM

-- July 6, 2026 --

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering Globe Newswire 4:05 PM

-- July 2, 2026 --

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering Globe Newswire 12:25 AM

-- June 29, 2026 --

Elicio Therapeutics Added to Russell 2000 and Russell 3000 Indexes Globe Newswire 8:00 AM

-- June 25, 2026 --

ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm Business Wire 3:01 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX PRNewswire 10:01 AM

-- June 23, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX Globe Newswire 5:32 PM

-- June 17, 2026 --

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer Globe Newswire 8:00 AM

-- June 16, 2026 --

Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) PRNewswire 4:44 PM

-- June 15, 2026 --

ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc. Globe Newswire 12:28 PM
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer Globe Newswire 7:00 AM

-- June 1, 2026 --

Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company's AMP-DNA Adjuvant Technology Globe Newswire 8:00 AM

-- May 11, 2026 --

Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 4:05 PM

-- April 30, 2026 --

Elicio Therapeutics to Present at the Bank of America Healthcare Conference Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes